ArticleNucleic acids research2021
DrugCentral 2021 supports drug discovery and repositioning.
Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma.Cancer biology & therapy · 2023Pooled it
- The evolving landscape of drug targets.Nature reviews. Drug discovery · 2026Review
- Multimodal Collaborative Modeling of Molecular Structures and Biomedical Text for Accurate Drug-Drug Interaction Extraction.Biomedicines · 2026Article
- Therapeutic target database 2026: facilitating targeted therapies and precision medicine.Nucleic acids research · 2026Article
- A multimodal vision knowledge graph of cardiovascular disease.Nature cardiovascular research · 2026Article
- MDG-DDI: multi-feature drug graph for drug-drug interaction prediction.BMC bioinformatics · 2025Article
- Accurate prediction of drug-protein interactions by maintaining the original topological relationships among embeddings.BMC biology · 2025Article
- SCATrans: semantic cross-attention transformer for drug-drug interaction predication through multimodal biomedical data.BMC bioinformatics · 2025Article
- A network pharmacology-based approach to understand the mechanism of action of anti-mycobacterial activity of Acacia nilotica: a modelling and experimental study.Molecular diversity · 2025Article
- Negative sampling strategies impact the prediction of scale-free biomolecular network interactions with machine learning.BMC biology · 2025Article
- Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential.International journal of molecular sciences · 2025Article
- Synergistic mechanism of olaparib and cisplatin on breast cancer elucidated by network pharmacology.Scientific reports · 2025Article
- CardioGenAI: a machine learning-based framework for re-engineering drugs for reduced hERG liability.Journal of cheminformatics · 2025Article
- DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease.Scientific reports · 2025Article
- CDPMF-DDA: contrastive deep probabilistic matrix factorization for drug-disease association prediction.BMC bioinformatics · 2025Article
- AMFGNN: an adaptive multi-view fusion graph neural network model for drug prediction.Frontiers in pharmacology · 2025Article
- Article
- Article
- Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study.Journal of pharmaceutical policy and practice · 2025Article
- A foundation model for clinician-centered drug repurposing.Nature medicine · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
DrugCentral is a public resource (http://drugcentral.org) that serves the scientific community by providing up-to-date drug information, as described in previous papers. The current release includes 109 newly approved (October 2018 through March 2020) active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities (e.g. mefuparib) of interest for COVID19. New additions include a set of pharmacokinetic properties for ∼1000 drugs, and a sex-based separation of side effects, processed from FAERS (FDA Adverse Event Reporting System); as well as a drug repositioning prioritization scheme based on the market availability and intellectual property rights forFDA approved drugs. In the context of the COVID19 pandemic, we also incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities, as well as the 'drugs in news' feature offers a brief enumeration of the most interesting drugs at the present moment. The full database dump and data files are available for download from the DrugCentral web portal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.